百濟神州/信達生物/九毛九急漲8%-13%後者破頂 今起獲納入港股通
九毛九(09922.HK)、信達生物(01801.HK)及百濟神州(06160.HK)今天起獲納入「港股通」,三股今早齊齊急漲,九毛九扭兩連吐股價再創上市新高,最高見19.9元,現造19.4元,急漲13%,成交增至2,294萬股,涉資4.17億元。
信達生物承上周五倒升勢,今早一舉升破20天、50天及10天線(52.65-53.85元),最高見59.1元,現造58.2元,急漲12%,成交增至1,252萬股,涉資7.15億元;百濟神州延續過去兩連彈勢,今早股價升破10天線(145元),最高見156元,創逾一個月高,現造153.5元,續升8%。
港交所資料顯示,因應恆生綜合大型股指數、中型股指數及小型股指數實施成份股定期調整,「港股通」股票名單今日起調整,26隻股份被調出;34股獲調入,其中包括九毛九、信達生物及百濟神州。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.